Bayer AG (XSWX:BAYN) 5-Year Yield-on-Cost %: 0.01 (As of Jul. 01, 2026) — 91% Below Median


XSWX:BAYN Bayer AG XSWX:BAYN
54 GF Score
Price CHF43.29
GF Value CHF24.61
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bayer AG 5-Year Yield-on-Cost %?

Bayer AG XSWX:BAYN +1.88% 54 5-Year Yield-on-Cost % is 0.01 as of Jul. 01, 2026, which is 91% below its 10-year median of 0.11. GuruFocus rates XSWX:BAYN with a GF Score™ of 54/100 and a GF Value™ of CHF24.61 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 516 Drug Manufacturers companies, Bayer AG ranks worse than 100% on this metric.

Bayer AG's yield on cost for the quarter that ended in Mar. 2026 was 0.01.


The historical rank and industry rank for Bayer AG's 5-Year Yield-on-Cost % or its related term are showing as below:

XSWX:BAYN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.01   Med: 0.11   Max: 0.27
Current: 0.01


During the past 13 years, Bayer AG's highest Yield on Cost was 0.27. The lowest was 0.01. And the median was 0.11.


XSWX:BAYN's 5-Year Yield-on-Cost % is ranked worse than
100% of 516 companies
in the Drug Manufacturers industry
Industry Median: 2.35 vs XSWX:BAYN: 0.01

Bayer AG  (XSWX:BAYN) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Bayer AG 5-Year Yield-on-Cost % Related Terms


XSWX:BAYN vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - General subindustry, Bayer AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bayer AG 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Bayer AG's 5-Year Yield-on-Cost % falls into.


XSWX:BAYN
54GF Score
Bayer AG XSWX:BAYN
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Bayer AG is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.01 mean?
Bayer AG (XSWX:BAYN) has a 5-Year Yield-on-Cost % of 0.01 as of Jul. 01, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bayer AG and its competitors. This is 91% below median its historical median of 0.11. Over the past decade, Bayer AG's 5-Year Yield-on-Cost % has ranged from 0.01 to 0.27. According to the industry distribution chart, Bayer AG ranks #516 out of 516 companies in the Drug Manufacturers industry.
Is Bayer AG's 5-Year Yield-on-Cost % too high?
Bayer AG's current 5-Year Yield-on-Cost % of 0.01 is 91% below median its 10-year median of 0.11. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.27. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.35. Bayer AG's value of 0.01 is 99.6% below this industry median. Based on the distribution chart, Bayer AG ranks #516 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bayer AG has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #516 out of 516 companies for 5-Year Yield-on-Cost %. This places Bayer AG in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.35. Bayer AG's value of 0.01 is 99.6% below this benchmark. Historically, Bayer AG's own 5-Year Yield-on-Cost % has ranged from 0.01 to 0.27 over the past decade. While the company's 10-year median is 0.11 vs. the industry median of 2.35, Bayer AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.35, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current 5-Year Yield-on-Cost % of 0.01 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current 5-Year Yield-on-Cost % is 0.01, which is 91% below median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.61, compared to a current price of CHF43.29 — trading 75.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.01, which is 91% below median its 10-year median of 0.11 and 99.6% below the Drug Manufacturers industry median of 2.35. Bayer AG's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current 5-Year Yield-on-Cost % is 0.01 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF43.29 is trading 75.9% above its estimated GF Value™ of CHF24.61. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • 5-Year Yield-on-Cost %: 0.01 (91% below median its 10-year median of 0.11)
  • GF Value™: CHF24.61 vs. price of CHF43.29 (75.9% above fair value)
  • GF Score™: 54/100 with 6 warning signs
  • Industry Position: 99.6% below the Drug Manufacturers median (#516 of 516)

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
54GF Score

Get the complete analysis for XSWX:BAYN

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF43.29
Price
CHF24.61
GF Value